cancerwall

102 results found.

Top Stocks matching your search for "cancer wall"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Oct, 28, 2022

$SLRX “These initial data explain why we believ... See more

Oct, 28, 2022

$SLRX SP-3164 showed significant tumor growth &q... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
HEPA

Hepion Pharmaceuticals Inc

-16.85%

$0.86 - $0.72

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 16, 2023

In addition to NASH, Rencofilstat appears to be e... See more

Feb, 17, 2023

but the Liver Cancer (HCC) indication and ability ... See more

Motley Fool
Discover Your Wealth Potential with Stock Advisor

The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.

*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.
02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$TGTX MOST CONVENIENT- 50% faster infusion SAFE... See more

Mar, 13, 2023

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Oct, 28, 2022

$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.

Oct, 28, 2022

$SLRX SP-3164 showed significant tumor growth "inhibition" in in vivo studies including statistically significant improvement over the approved immunomodulatory drugs lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)

HEPA

Hepion Pharmaceuticals Inc

-16.85%

$0.86 - $0.72

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 16, 2023

In addition to NASH, Rencofilstat appears to be effective against Multiple Myeloma and Prostate Cancer.

Feb, 17, 2023

but the Liver Cancer (HCC) indication and ability to treat alcohol liver disease alone make Rencofilstat a potential top tier therapeutic - on top of NASH.

Feb, 1, 2023

This makes Rencofilstat a promising candidate for the treatment of a variety of diseases, including thromboembolic disorders, sepsis, and cancer.

Jan, 11, 2023

This cancer stuff is very promising indeed,

Jan, 11, 2023

It is regarded as an incredible drug that almost cures cancer.

Jan, 10, 2023

“killed 70% – 90% of the cancer cells (4 different cell lines) over two days.

TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$TGTX MOST CONVENIENT- 50% faster infusion SAFEST - Zero Breast Cancer Risk MOST AFFORDABLE - By far If TGTX was a Big Pharma Company, the medical press would be blowing it up with praise.

Mar, 13, 2023

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

Feb, 3, 2023

- Lowest ARR rate, no black box label, reduced brain lesions, and no reports of breast cancer.

Jan, 27, 2023

Lowest ARR rate, no black box warning label, reduced brain lesions, and no reports of breast cancer (there are reports of breast cancer with other MS treatments, and 75% of people with MS are women).

Jan, 16, 2023

$TGTX "4 Stories of Living with Multiple Sclerosis" Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.

Jan, 12, 2023

No breast cancer risk.

Jan, 10, 2023

Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition

Jan, 6, 2023

$TGTX possibly the best therapy available for MS patients that exists today!

Jan, 5, 2023

MS is 3 times more common in women and there were no reports of breast cancer compared to the competition!